Allocation of costs and compensation when a case has become groundless

Case No. O2012_025 ¦ Decision of 16 July 2012 ¦ “Gegenstandslosigkeit; Kosten- und Entschädigungsfolgen”

This case pertains to EP 1 175 904 B1 of Merck & Co., Inc., claiming the

[u]se of alendronate in the manufacture of a medicament for treating osteoporosis in a human in need of such treatment, where said medicament is orally administered to said human as a unit dosage comprising about 70 mg of the alendronate compound, on an alendronic acid active weight basis, according to a continuous schedule having a once-weekly dosing interval.

→  Read more ...